This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

How the U.S. Government Makes Money on Cannabis

NEW YORK (TheStreet) -- The government makes money off of cannabis; the same cannabis it declares illegal. The same cannabis it throws people into prison for selling.

The National Institute of Health received a patent on cannabinoids in October 2003. Aidan Hampson, the scientist who made the discovery while working at the Institute of Mental Health said, "I discovered the cannabinoid receptor in the brain that THC [the active chemical in marijuana] binds to. THC mimics something that occurs naturally in the brain and I asked myself, what's the natural key to this lock?" Hampson said if a scientist believes something could be important, then you patent it immediately.

"Any discovery you make, you hope it has a therapeutic benefit," said Hampson. In order to eventually get that discovery to patients, a drug needs to go through clinical trials. No drug company will pursue drug development unless they know who owns the intellectual property. "It would cost approximately $30 million to do a test." said Hampson. "No company will give you a second glance unless you own the intellectual property." Meaning, they won't want to spend the money unless they can recoup the cost of the test and they need the patent or a license on the drug in order to do so.

In June of 2013, the NIH granted the exclusive license to phyto-medical company KannaLife Sciences. Dean Petkanus CEO of KannaLife said it was very difficult to get the exclusive license to the patent. The company has the license for only one disease, Hepatic Encephalopathy, that is associated with liver disorders. It occurs in people with cirrhosis from alcoholism or hepatitis C and B as a couple of examples.

Petkanus believes that KannaLife's product could be a $1 billion-to-$2 billion drug with a potential patient population of 1.5 million. Petkanus would not say how much they would have to pay to NIH as a result of the agreement saying, "We can't disclose the terms." However, KannaLife has made several payments already to NIH for royalty fees, continuous use fees and prosecution fees. "We have made payments to the NIH. Absolutely," said Petkanus.

The patent expires in February 2021, but KannaLife believes it will have a product to market before that time. KannaLife also believes the product will have FDA approval which means the FDA would have to reschedule the classification of cannabis.

Marijuana is currently defined as a schedule 1 controlled substance meaning it is a dangerous drug and has no medicinal benefits (even though the NIH filed for the patent stating the cannabinoids could treat diseases like Alzheimer's, Parkinson's, HIV and could limit damage in strokes and trauma.) Congress has many pieces of legislation addressing marijuana, but isn't expected to change the status anytime soon.

Allen St. Pierre of NORML believes that the government wants to have sole control of the cannabis patent and that others have requested it and haven't received it. However, several mainstream pharmacology companies have received patents including GW Pharmaceuticals (GWPH), AbbVie (ABBV - Get Report). a spinoff of Abbot Laboratories. and Jenrin Discovery.

Mark Rogerson of GW Pharmaceuticals confirmed that "it has an extensive intellectual property portfolio that includes multiple patents directed to the plants, plant extracts, extraction technology, pharmaceutical formulations, drug delivery, and therapeutic uses of cannabinoids. In the treatment of cancer pain, we have a patent in the United States that expires 2026." Rogerson went on to say, "Our patent strategy is to cover all key territories and it therefore includes the United States, the European Union, Japan and other selected markets."

Neither Jenrin or AbbVie returned calls for information.

Hampson suggested that the NIH would protect its cannabinoid patent if it had to -- adding to the irony that one agency within the Department of Health and Human Services will protect its ability to make money off of cannabis, while another HHS agency, the Food and Drug Administration declares marijuana a dangerous drug.

Cannabis-Rx Is Growing the Field of Marijuana Real Estate

Washington State Sees July 1st for Marijuana Kickoff

-- Written by Debra Borchardt in New York.

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABBV $61.13 -0.03%
GWPH $84.52 1.99%
AAPL $118.88 0.96%
FB $105.74 -1.13%
GOOG $748.28 -1.02%


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs